MECOM and breast cancer: One study of 608 randomly collected breast cancer cases found EVI1 to be expressed in estrogen receptor (ER)-positive as well as ER-negative patients and also found EVI1 to be a prognostic marker in ER-negative and especially in triple-negative breast cancer (TNBC) patients [1].